Subscribe to our Newsletters !!
In molecular biology, the LAMP (Loop-Mediated Isot
Pharmaceutical laboratories have been adopting imm
Generally, a debate about Isopure protein and regu
Alembic Pharmaceuticals Limited appoints Mr. Manis
The importance of comparing the treatment of asthm
It is important to understand that natural remedie
In a world constantly in motion, Microbioz India r
The COVID-19 pandemic has resulted in unprecedented disruption for the healthcare industry, pushing government, health agencies battling infectious diseases, healthcare workers, and diagnostic labs to think about alternative ways of delivering health care while adapting to the new environment. Sharing insights and learnings from the COVID-19 pandemic by Mr. Amit Chopra, Managing Director, Thermo Fisher Scientific, India and South Asia.
Mr. Amit Chopra, Managing Director, Thermo Fisher Scientific, India and South Asia.
The world witnessed one of the biggest and toughest health crises in the form of COVID-19. At Thermo Fisher Scientific, we continue our response to the pandemic and are truly energized by the role we play in enabling our customers to also respond in a significant way. Some of the key lessons we have learned along the way include-:
Strengthening the healthcare ecosystem:
The pandemic has clearly articulated the need for an agile and robust healthcare infrastructure. Vaccines alone cannot get us out of this. We need vaccines, therapeutics and diagnostics to make sure that we can prevent, identify and treat COVID cases in a variety of populations. Early in the pandemic, we recognized the need to invest in innovative testing technology that can not only offer superior sensitivity and specificity to detect the virus, as well as the need to ramp up our production timelines to make sure there was plenty of supply in terms of testing for COVID-19.. Additionally, establishing mechanisms to understand the global patterns of transmission and monitor regional and local spread of SAR-CoV-2 would be another crucial aspect to manage through the second wave.
The value of partnerships and collaboration:
A critical aspect of our response to COVID-19 was recognizing the need for collaboration to help meet the demand for more tests, wider distribution of tests, personal protective equipment and much more as cases once again spiked globally this fall.. It is reassuring to witness how the government, industry, researchers, and healthcare professionals globally have come together to address the challenge at hand.
Adoption of digital technologies:
Digital technologies and capabilities have transformed the way we do our work or interact with our customers. Digital technologies have enabled organization to create and implement strategies that accelerate scientific advancements, improve customer experience, and empower companies to make strategic data-driven decisions.
Overall, we continue to build on the significant progress we have made in 2020 as our response to COVID-19. These efforts have not only enabled us to effectively navigate through this environment but also position us stronger for the future and making us valuable partners for our customers.
